No Winner In Nanjing Medical And Xian-Janssen Breakup
This article was originally published in PharmAsia News
Executive Summary
After breaking up their collaboration in 2007, Nanjing Medical and Xian-Janssen have made no progress in resuming their business negotiation. Xian-Janssen, the biggest OTC producer in China, has found another channel partner in Nanjing; Nanjing Medical on its part has taken up distributorship of alternative products. The standoff has not benefited either party. Xian-Janssen's key drug Motilium sees lower sales, while Nanjing Medical's newly released 2007 annual report shows that its pharmaceutical distribution profit growth only increased 0.21 percentage points compared to the previous year. Industry observers note that to achieve a win-win situation, pharmaceutical producers should give reasonable profit margins to distributors, which in turn should value the manufacturers' brand names. (Click here for more - Chinese Language)
You may also be interested in...
Xian-Janssen And Nanjing Medical Resume Collaboration On Drug Distribution
Nanjing Medical and Xian-Janssen have ended their dispute over drug distribution (PharmAsia News, March 31, 2008), according to an insider, but the detailed compromise solution is not disclosed. The strained relations between the two firms have impacted Xian-Janssen's revenue, which dropped 20 to 30 percent in 2008. Based on the previous model, Nanjing Medical is now directly distributing Xian-Janssen's drugs in Fujian and Anhui provinces. However, Jiangsu is covered by Nanjing Huadong Medicine, which is Nanjing Medical's sister subsidiary under Nanjing Medical Industry (Group). The move shows Xian-Janssen's willingness to work indirectly with Nanjing Medical to avoid losing the latter's Jiangsu clients comprising 167 hospital pharmacies. (Click here for more - Chinese Language)
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.